The answer is in your ? stagman. Why would a director buy at 2.3c 160K and then dilute the stock. This will be heading north.Short term pain for long term gain/risk. I think there is more to this story that will unfold.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential